Drug intelligence / Profile preview

GSK3206640A

Development stage: Phase 1
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK3206640A is an investigational monovalent inactivated influenza vaccine candidate developed by GSK for the prevention of H7N9 avian influenza. It consists of 15 µg of hemagglutinin (HA) antigen derived from the A/Shanghai/2/2013 (H7N9) strain, formulated with the AS03 adjuvant system (an oil-in-water emulsion containing squalene and alpha-tocopherol). The vaccine was evaluated in clinical trials to assess its safety and immunogenicity in adults, particularly in the context of pandemic preparedness against H7N9 influenza viruses, which have shown potential for human-to-human transmission.

Other names: H7N9 AS03-adjuvanted vaccine (15 µg)GSK H7N9 influenza vaccineH7N9 influenza vaccineH-7N9 influenza vaccineH 7N9 influenza vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on GSK3206640A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3206640A.

Explore the full profile